FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design

FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss
Proellex(R)-V Phase 3 Study Design

THE WOODLANDS, Texas, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced that the FDA has agreed to a Type B
meeting scheduled for the last half of May to discuss the Phase 3 development
of Proellex® as a vaginally administered product for the treatment of uterine
fibroids. During the meeting, Repros will discuss the proposed plans for a
Phase 3 study, the FDA's requirements for the size of the safety population
and the adequacy of the already completed preclinical studies to support a
marketing application.

Once the meeting is held, the Company will report the outcome to the financial
community in a timely fashion.

About Repros Therapeutics Inc. ^ ®

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal^®
and Proellex^® programs, have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

The Repros Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7738

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
        
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo
 
Press spacebar to pause and continue. Press esc to stop.